Moderna Inc said on Thursday it has dosed the first participant in a mid-to-late stage study testing its COVID-19 vaccine candidate in adolescents aged 12 to less than 18.
Comments
The commenter agrees to the privacy policy of Ynet News and agrees not to submit comments that violate the terms of use, including incitement, libel and expressions that exceed the accepted norms of freedom of speech.